At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
MK-8892 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension
In Brief
A Phase 1 clinical trial evaluating MK-8892 and Placebo for MK-8892 for Pulmonary Arterial Hypertension. Completed, enrolled 23 participants.
Detailed Summary
This study will evaluate the safety, tolerability, and PK of MK-8892 in participants with pulmonary arterial hypertension. The primary hypothesis is that the geometric mean of MK-8892 area under the concentration time-curve from Hour 0 to 24 hours (AUC0-24hr) in participants with PAH, will be equal to or greater than the efficacious exposure in humans of 0.6 μM•hr.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartNov 2013
Primary CompletionSep 2014
Study CompletionSep 2014
TodayJul 2026
First PostedAug 21, 2013
Enrollment StartNov 14, 2013
Primary CompletionSep 1, 2014
Study CompletionSep 8, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.9 years ago
Interventions
MK-8892drug
Placebo for MK-8892drug